210 related articles for article (PubMed ID: 37516994)
61. Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?
Solari D; Pivonello R; Caggiano C; Guadagno E; Chiaramonte C; Miccoli G; Cavallo LM; Del Basso De Caro M; Colao A; Cappabianca P
World Neurosurg; 2019 Jul; 127():695-709. PubMed ID: 31266132
[TBL] [Abstract][Full Text] [Related]
62. Aggressive pituitary tumors and carcinomas: medical treatment beyond temozolomide.
DE Alcubierre D; Carretti AL; Ducray F; Jouanneau E; Raverot G; Ilie MD
Minerva Endocrinol (Torino); 2024 Jan; ():. PubMed ID: 38240681
[TBL] [Abstract][Full Text] [Related]
63. Long-Term Survival After Transformation of an Adrenocorticotropic Hormone-Secreting Pituitary Macroadenoma to a Silent Corticotroph Pituitary Carcinoma.
Rotman LE; Vaughan TB; Hackney JR; Riley KO
World Neurosurg; 2019 Feb; 122():417-423. PubMed ID: 30447452
[TBL] [Abstract][Full Text] [Related]
64. Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.
Elbelt U; Schlaffer SM; Buchfelder M; Knappe UJ; Vila G; Micko A; Deutschbein T; Unger N; Lammert A; Topuzoglu-Müller T; Bojunga J; Droste M; Johanssen S; Kolenda H; Ritzel K; Buslei R; Strasburger CJ; Petersenn S; Honegger J
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31746334
[TBL] [Abstract][Full Text] [Related]
65. Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide.
Tanaka S; Yamamoto M; Morita M; Takeno A; Kanazawa I; Yamaguchi T; Yamada S; Inoshita N; Oki Y; Kurosaki M; Sugimoto T
Endocr J; 2019 Aug; 66(8):701-708. PubMed ID: 31130573
[TBL] [Abstract][Full Text] [Related]
66. Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?
Ogawa Y; Jokura H; Niizuma K; Tominaga T
J Neurooncol; 2018 May; 137(3):543-549. PubMed ID: 29318507
[TBL] [Abstract][Full Text] [Related]
67. Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors.
Nakano-Tateno T; Lau KJ; Wang J; McMahon C; Kawakami Y; Tateno T; Araki T
Front Endocrinol (Lausanne); 2021; 12():624686. PubMed ID: 33841328
[TBL] [Abstract][Full Text] [Related]
68. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.
Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P
Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912
[TBL] [Abstract][Full Text] [Related]
69. Recurrent non-functioning pituitary adenomas: a review on the new pathological classification, management guidelines and treatment options.
Delgado-López PD; Pi-Barrio J; Dueñas-Polo MT; Pascual-Llorente M; Gordón-Bolaños MC
Clin Transl Oncol; 2018 Oct; 20(10):1233-1245. PubMed ID: 29623588
[TBL] [Abstract][Full Text] [Related]
70. Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Yamamoto M; Nakao T; Ogawa W; Fukuoka H
Front Endocrinol (Lausanne); 2021; 12():650791. PubMed ID: 34220707
[TBL] [Abstract][Full Text] [Related]
71. Atypical pituitary adenoma: a clinicopathologic case series.
Rutkowski MJ; Alward RM; Chen R; Wagner J; Jahangiri A; Southwell DG; Kunwar S; Blevins L; Lee H; Aghi MK
J Neurosurg; 2018 Apr; 128(4):1058-1065. PubMed ID: 28598278
[TBL] [Abstract][Full Text] [Related]
72. Silent corticotroph adenomas.
Karavitaki N; Ansorge O; Wass JA
Arq Bras Endocrinol Metabol; 2007 Nov; 51(8):1314-8. PubMed ID: 18209869
[TBL] [Abstract][Full Text] [Related]
73. Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas.
Minniti G; Paolini S; Rea MLJ; Isidori A; Scaringi C; Russo I; Osti MF; Cavallo L; Esposito V
J Neurooncol; 2020 Aug; 149(1):123-130. PubMed ID: 32632895
[TBL] [Abstract][Full Text] [Related]
74. Adrenocorticotropic hormone-producing pituitary carcinoma with intracranial metastases.
Shastri BR; Nanda A; Fowler M; Levine SN
World Neurosurg; 2013 Feb; 79(2):404.e11-6. PubMed ID: 22079280
[TBL] [Abstract][Full Text] [Related]
75. Aggressive pituitary tumors in the young and elderly.
Tatsi C; Stratakis CA
Rev Endocr Metab Disord; 2020 Jun; 21(2):213-223. PubMed ID: 31912365
[TBL] [Abstract][Full Text] [Related]
76. Pituitary Carcinoma in a Patient with an SDHB Mutation.
Tufton N; Roncaroli F; Hadjidemetriou I; Dang MN; Dénes J; Guasti L; Thom M; Powell M; Baldeweg SE; Fersht N; Korbonits M
Endocr Pathol; 2017 Dec; 28(4):320-325. PubMed ID: 28284009
[TBL] [Abstract][Full Text] [Related]
77. Medical therapy for refractory pituitary adenomas.
Geer EB
Pituitary; 2023 Jun; 26(3):303-306. PubMed ID: 37115295
[TBL] [Abstract][Full Text] [Related]
78. Non-functioning pituitary tumors: 2012 update.
Cámara Gómez R
Endocrinol Nutr; 2014 Mar; 61(3):160-70. PubMed ID: 24035732
[TBL] [Abstract][Full Text] [Related]
79. Silent pituitary adenomas.
Mayson SE; Snyder PJ
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):79-87. PubMed ID: 25732644
[TBL] [Abstract][Full Text] [Related]
80. Management of Aggressive Pituitary Tumors - A 2019 Update.
Petersenn S
Horm Metab Res; 2019 Dec; 51(12):755-764. PubMed ID: 31826270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
